Allscripts Healthcare Solutions Company Profile (NASDAQ:MDRX)

Allscripts Healthcare Solutions trades on the NASDAQ under the ticker symbol "MDRX."

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) posted its earnings results on Thursday, August, 3rd. The company reported $0.11 EPS for the quarter, missing the Zacks' consensus estimate of $0.15 by $0.04. The company earned $426.10 million during the quarter, compared to analysts' expectations of $424.94 million. Allscripts Healthcare Solutions had a negative net margin of 11.54% and a positive return on equity of 5.97%. The company's quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the business earned $0.14 earnings per share. View Allscripts Healthcare Solutions' Earnings History.

Allscripts Healthcare Solutions is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Allscripts Healthcare Solutions.

Allscripts Healthcare Solutions issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $0.61-0.63 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.62.

17 brokers have issued 12-month price objectives for Allscripts Healthcare Solutions' shares. Their forecasts range from $12.00 to $19.00. On average, they expect Allscripts Healthcare Solutions' share price to reach $14.43 in the next year. View Analyst Ratings for Allscripts Healthcare Solutions.

Here are some recent quotes from research analysts about Allscripts Healthcare Solutions stock:

• 1. Cantor Fitzgerald analysts commented, "2Q17 recap. Non-GAAP revenue was $428 million compared to FactSet consensus of $426 million. With Netsmart now mostly annualized, non-GAAP revenue grew 7.8% y/y. Adjusted EPS was $0.15 (in line with our estimate and consensus) vs. $0.14 a year ago. Bookings were impressive and grew to $407 million." (8/14/2017)
• 2. According to Zacks Investment Research, "Allscripts exited the second quarter on a favorable note, wherein adjusted earnings were in line with the Zacks Consensus Estimate, while revenues beat the same. Over the last year, Allscripts has traded below the broader industry in terms of price. A solid guidance for full-year 2017 and a strong long-term outlook are the key highlights at the moment. Allscripts announced its plans to takeover the hospital and health system business from McKesson Corporation, which is expected to close by the fourth quarter. Allscripts’ continued reliance on mergers and acquisition activities presents a substantial integration risk for the company. Furthermore, intensifying market competition is a major dampener for Allscripts. The company also expects a modest increase in operating expenses during the second half of the year to support business growth." (8/9/2017)
• 3. Maxim Group analysts commented, "1Q17 bookings of $286M, up 13.5% y/y, were below our estimate of $302M and consensus of $298M." (5/5/2017)
• 4. Citigroup Inc. analysts commented, "We are upgrading MDRX shares to Buy following its recent analyst day. Allscripts provided targets for 2018 - 2020 revenue growth of 6%-8% and EPS growth of 12%-15%, both of which are ahead of our forecasts but approximately in-line with the Street. Allscripts is beginning to show better results as non-recurring revenue has stabilized, recurring revenue grows faster, and the mix continues to shift to recurring revenue, with non EMR solutions seeing faster growth. We believe that if Allscripts can hit these targets investors could see a 20% return on the shares this year from current levels." (3/24/2017)
• 5. Piper Jaffray Companies analysts commented, "We attended Allscripts' Investor Conference yesterday where management discussed its plan to deliver its FY17 guidance and long term growth targets. We believe 6-8% revenue growth and 12-15% EPS growth are achievable, provided the non-recurring revenue has surpassed its decline, and the Platform as a Service model continues to grow. We are tapering our FY18 EPS estimate to be in line with targets while maintaining our 20x EPS valuation, which brings our PT to $14 from $15. Reiterate Neutral." (3/22/2017)

Allscripts Healthcare Solutions saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 26,142,549 shares, an increase of 0.9% from the July 14th total of 25,906,388 shares. Based on an average daily trading volume, of 2,336,288 shares, the short-interest ratio is currently 11.2 days. Currently, 14.7% of the company's shares are short sold.

Some companies that are related to Allscripts Healthcare Solutions include Cotiviti Holdings (COTV), HealthEquity (HQY), Omnicell (OMCL), Evolent Health (EVH), Emis Group Plc (EMIS), Castlight Health, inc. (CSLT), NantHealth (NH), Craneware plc (CRW), Tabula Rasa Healthcare (TRHC), Simulations Plus (SLP), Fluidigm Corporation (FLDM), Medical Transcription Billing, Corp. (MTBC), Constellation Healthcare Tech (CHT) and Press Ganey Holdings (PGND).

Allscripts Healthcare Solutions' management team includes the folowing people:

• Michael A. Klayko, Independent Chairman of the Board
• Richard J. Poulton, President
• Paul M. Black, Chief Executive Officer, Director
• Dennis M. Olis, Interim Chief Financial Officer, Principal Accounting Officer
• James R. Hewitt, Executive Vice President, Solutions Development
• Lisa Khorey, Executive Vice President, Chief Client Delivery Officer
• Brian P. Farley, Senior Vice President, General Counsel and Corporate Secretary;
• Mara Glickman Aspinall, Independent Director
• P. Gregory Garrison, Independent Director
• Jonathan J. Judge, Independent Director

Allscripts Healthcare Solutions' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.17%), Iridian Asset Management LLC CT (6.95%), Dimensional Fund Advisors LP (5.05%), Fiduciary Management Inc. WI (3.35%), State Street Corp (3.31%) and First Trust Advisors LP (3.22%). Company insiders that own Allscripts Healthcare Solutions stock include Brian Farley, Dennis Olis, James Hewitt, Paul Black and Richard J Poulton. View Institutional Ownership Trends for Allscripts Healthcare Solutions.

Allscripts Healthcare Solutions' stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, Schwab Charles Investment Management Inc., Cornerstone Capital Management Holdings LLC., Broadview Advisors LLC, Iridian Asset Management LLC CT, New York State Common Retirement Fund, OxFORD Asset Management LLP and Neuberger Berman Group LLC. Company insiders that have sold Allscripts Healthcare Solutions stock in the last year include Brian Farley, James Hewitt, Paul Black and Richard J Poulton. View Insider Buying and Selling for Allscripts Healthcare Solutions.

Allscripts Healthcare Solutions' stock was bought by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Dimensional Fund Advisors LP, Mesirow Financial Investment Management Equity Management, State Street Corp, Northern Trust Corp, Boston Partners, Russell Investments Group Ltd. and Royal Bank of Canada. View Insider Buying and Selling for Allscripts Healthcare Solutions.

Shares of Allscripts Healthcare Solutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Allscripts Healthcare Solutions stock can currently be purchased for approximately $12.85.